Zobrazeno 61 - 70
of 122
pro vyhledávání: '"Ben Markman"'
Autor:
Vincent Chow, Florian D. Vogl, Gloria Juan, Erik Rasmussen, Oscar B. Goodman, Montaser Shaheen, Ben Markman, Michael A. Carducci, Jayesh Desai, Dusan Kotasek, Sara A. Hurvitz, Daruka Mahadevan, Erick Gamelin, Gregory Friberg
Publikováno v:
Investigational new drugs, vol 36, iss 6
Background Aurora kinase overexpression or amplifications are associated with high proliferation, poor prognosis, and therapeutic resistance in human tumors. AMG 900 is an investigational, oral, selective pan-Aurora kinase inhibitor. Methods This fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3efca95b889209005d178b38046436b5
https://escholarship.org/uc/item/3kw4205f
https://escholarship.org/uc/item/3kw4205f
Autor:
Ben Markman, Z. Qin, Jermaine Coward, Y. Ma, John J. Park, A.N. Tse, Dusan Kotasek, Sarwan Bishnoi, Michael P. Brown, Amy Prawira, R.M. Strother, R. Eek, J. Kuo, R. Chen, Q. Zhang, D. Day, Lisa Wang, Charlotte Lemech
Publikováno v:
Annals of Oncology. 31:S722
Autor:
Nageshwar Budha, Paul S. Foster, Mark Voskoboynik, Ben Markman, Jing Song, Sophia Frentzas, Tarek Meniawy, Jayesh Desai
Publikováno v:
Cancer Research. 80:CT253-CT253
Background: Programmed cell death protein-1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), play critical roles in the immune modulation of tumor progression. Although both pathways have overlapping elements, each has a distinct mechanism o
Autor:
Ben Markman, Clare L. Scott, Andreas Behren, Yeojeong So, Jonathan Cebon, Oliver Klein, Damien Kee, Matteo S. Carlino, Richelle Linklater, Bo Gao, Linda Mileshkin, Jodie Palmer
Publikováno v:
Journal of Clinical Oncology. 38:6091-6091
6091 Background: Up to 50% of gynecological cancers are considered rare. The outcome of these patients (pts) is poor given a lack of scientific and clinical knowledge. Immunotherapy using single agent anti- PD-1/PD-L1 treatment (tx) has shown only mo
Autor:
Andreas Behren, Adnan Nagrial, Oliver Klein, Jodie Palmer, Matteo S. Carlino, Damien Kee, Michael Michael, Craig Underhill, Jonathan Cebon, Niall C. Tebbutt, Caroline Lum, Ben Markman
Publikováno v:
Journal of Clinical Oncology. 38:4588-4588
4588 Background: Patients (pts) with advanced biliary tract cancers (BTC) have a poor prognosis with first and second line chemotherapy resulting in modest survival benefits. Immunotherapy using single agent anti-PD-1 therapy has also shown low activ
Autor:
Ben Markman, Grant A. McArthur, Benjamin Solomon, Andrew Fellowes, Michael Millward, Elly Lynch, Rona Weerasuriya, Damien Kee, Jayesh Desai, Hui K Gan, Clare L. Scott, Clara Gaff, Ben Tran, Dong Anh Khuong-Quang, Kortnye Smith, Melissa Martyn, Kenneth J. O'Byrne, Stephen B. Fox, Sophie O Haire, Paul G Ekert
Publikováno v:
Journal of Clinical Oncology. 38:2033-2033
2033 Background: Despite increasing evidence of benefit supporting CGP in personalizing cancer therapy, its widespread uptake remains limited. Barriers include low patient understanding, unmet patient expectations related to low utility, clinician co
Autor:
Andreea Varga, Carlos Gomez-Roca, Paul Basciano, F. de Braud, Zhaohui Liu, Victor Moreno, Ben Markman, Alex Azrilevich, Anthony M. Joshua, Matteo S. Carlino, Megan Wind-Rotolo, Jason J. Luke, Jayesh Desai, Sandip Pravin Patel, Yuko Ishii, J. Tabernero, Giuseppe Curigliano, L.L. Siu, Karen A. Gelmon
Publikováno v:
European Urology Supplements. 18:e1509-e1510
Autor:
Ben Markman, Manuel Hidalgo, D. Harris, Michael B. Jameson, Dusan Kotasek, Michael Millward, Robert Joseph Stagg, Mark J. McKeage, Ann M. Kapoun, Lu Xu, Brett G.M. Hughes
Publikováno v:
Targeted oncology. 13(1)
Delta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance of chemotherapy-resistant cancer stem cells and tumor vasculature. This phase IB trial of demcizumab, an IgG2 humanized monoclonal antibody directed against DLL4, was und
Autor:
Beena Kumar, Daniel J. Gough, D. Neil Watkins, Muhammad Alamgeer, Ilia Banakh, Vinod Ganju, Ben Markman
Publikováno v:
Investigational new drugs. 36(2)
Preclinical studies in small cell lung cancer (SCLC) have shown that hyaluronic acid (HA) can be effectively used to deliver chemotherapy and selectively decrease CD44 expressing (stem cell-like) tumour cells. The current study aimed to replicate the
Autor:
Andrew F. Hill, Kiheon Lee, C-C. Lin, Chang-Hsien Lu, Jayesh Desai, Michael Friedlander, Yee Chao, J. Hou, Michael B. Jameson, Ben Markman, John Wu, C.-J. Yen, Bhumsuk Keam, Kun-Ming Rau, Y-K Kang, Michael Millward, Ming-Mo Hou, Jung-Gon Lee, Lisa G. Horvath, Sanjeev Deva
Publikováno v:
Annals of Oncology. 29:x24-x25